The Epidemic of HPV-Associated Oropharyngeal Cancer Is Here: Is It Time to Change Our Treatment Paradigms?

2011 ◽  
Vol 9 (6) ◽  
pp. 665-673 ◽  
Author(s):  
Erich M. Sturgis ◽  
K. Kian Ang
Keyword(s):  
Clinical Trial ◽  
Human Papillomavirus ◽  
Head And Neck ◽  
Oropharyngeal Cancer ◽  
Head And Neck Cancers ◽  
Population Changes ◽  
Clinical Behavior ◽  
Incidence Trends

Although relatively uncommon, oropharyngeal cancers are increasing in incidence despite declining prevalence of smoking and in direct opposition to a decreasing incidence of all other head and neck cancers. An epidemic of human papillomavirus (HPV)–associated oropharyngeal cancers seems to account for these incidence trends. Important demographic, behavioral, and prognostic characteristics define this unique population. Changes in prevention, diagnosis, evaluation, staging, and treatment are needed. This article summarizes the epidemiology and clinical behavior of HPV-associated oropharyngeal cancer and discusses evolving/potential paradigms of treatment. However, data are currently insufficient to change treatment paradigms for HPV-associated oropharyngeal cancer outside of a closely monitored clinical trial.

scholarly journals Incidence trends for potentially human papillomavirus-related and -unrelated head and neck cancers in France using population-based cancer registries data: 1980-2012

2017 ◽  
Vol 140 (9) ◽  
pp. 2032-2039 ◽  
Author(s):  
Karine Jéhannin-Ligier ◽  
Aurélien Belot ◽  
Anne-Valérie Guizard ◽  
Nadine Bossard ◽  
Guy Launoy ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Cancer Registries ◽  
Population Based ◽  
Head And Neck Cancers ◽  
Incidence Trends

Psychosocial outcomes of human papillomavirus (HPV)‐ and non‐HPV‐related head and neck cancers: A longitudinal study

2021 ◽  
Author(s):  
Melissa Henry ◽  
Emily Arnovitz ◽  
Saul Frenkiel ◽  
Michael Hier ◽  
Anthony Zeitouni ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Longitudinal Study ◽  
Head And Neck ◽  
Psychosocial Outcomes ◽  
Head And Neck Cancers

Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status

Head & Neck ◽  
2013 ◽  
Vol 36 (6) ◽  
pp. 802-810 ◽  
Author(s):  
Steven Habbous ◽  
Luke T. G. Harland ◽  
Anthony La Delfa ◽  
Ehab Fadhel ◽  
Wei Xu ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Head And Neck Cancers

scholarly journals Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates

2018 ◽  
Vol 95 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Koh Jun Ong ◽  
Marta Checchi ◽  
Lorna Burns ◽  
Charlotte Pavitt ◽  
Maarten J Postma ◽  
...  
Keyword(s):  
Systematic Review ◽  
Human Papillomavirus ◽  
Head And Neck ◽  
Anal Cancer ◽  
Penile Cancer ◽  
Vulvar Cancer ◽  
Head And Neck Cancers ◽  
Economic Evaluations ◽  
Anogenital Warts ◽  
Utility Elicitation

BackgroundMany economic evaluations of human papillomavirus vaccination should ideally consider multiple disease outcomes, including anogenital warts, respiratory papillomatosis and non-cervical cancers (eg, anal, oropharyngeal, penile, vulvar and vaginal cancers). However, published economic evaluations largely relied on estimates from single studies or informal rapid literature reviews.MethodsWe conducted a systematic review of articles up to June 2016 to identify costs and utility estimates admissible for an economic evaluation from a single-payer healthcare provider’s perspective. Meta-analyses were performed for studies that used same utility elicitation tools for similar diseases. Costs were adjusted to 2016/2017 US$.ResultsSixty-one papers (35 costs; 24 utilities; 2 costs and utilities) were selected from 10 742 initial records. Cost per case ranges were US$124–US$883 (anogenital warts), US$6912–US$52 579 (head and neck cancers), US$12 936–US$51 571 (anal cancer), US$17 524–34 258 (vaginal cancer), US$14 686–US$28 502 (vulvar cancer) and US$9975–US$27 629 (penile cancer). The total cost for 14 adult patients with recurrent respiratory papillomatosis was US$137 601 (one paper).Utility per warts episode ranged from 0.651 to 1 (12 papers, various utility elicitation methods), with pooled mean EQ-5D and EQ-VAS of 0.86 (95% CI 0.85 to 0.87) and 0.74 (95% CI 0.74 to 0.75), respectively. Fifteen papers reported utilities in head and neck cancers with range 0.29 (95% CI 0.0 to 0.76) to 0.94 (95% CI 0.3 to 1.0). Mean utility reported ranged from 0.5 (95% CI 0.4 to 0.61) to 0.65 (95% CI 0.45 to 0.75) (anal cancer), 0.59 (95% CI 0.54 to 0.64) (vaginal cancer), 0.65 (95% CI 0.60 to 0.70) (vulvar cancer) and 0.79 (95% CI 0.74 to 0.84) (penile cancer).ConclusionsDifferences in values reported from each paper reflect variations in cancer site, disease stages, study population, treatment modality/setting and utility elicitation methods used. As patient management changes over time, corresponding effects on both costs and utility need to be considered to ensure health economic assumptions are up-to-date and closely reflect the case mix of patients.

Human papillomavirus: a cause of some head and neck cancers?

2004 ◽  
Vol 181 (8) ◽  
pp. 415-416 ◽  
Author(s):  
Barbara R Rose ◽  
Christopher J O'Brien ◽  
Wei Li
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Head And Neck Cancers

scholarly journals Human papillomavirus and head and neck cancers: emerging trends and improving survival

2012 ◽  
Vol 36 (2) ◽  
pp. 195-196 ◽  
Author(s):  
Julia M.L. Brotherton ◽  
Alicia N. Stein ◽  
E. Lynne Conway ◽  
David G. Regan ◽  
Andrew Grulich ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Head And Neck Cancers ◽  
Emerging Trends
Sign in / Sign up

Export Citation Format

Share Document